Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
UBS
Daiichi Sankyo
Citi
Queensland Health
Covington
Harvard Business School
Mallinckrodt

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,691,880

« Back to Dashboard

Which drugs does patent 7,691,880 protect, and when does it expire?

Patent 7,691,880 protects METHYLIN and is included in one NDA.

This patent has ten patent family members in nine countries.
Summary for Patent: 7,691,880
Title:Methylphenidate solution and associated methods of administration and production
Abstract:A methylphenidate solution and associated methods of administration and production, which includes methylphenidate and at least one organic acid dissolved in a solvent system, where the solvent system includes at least one non-aqueous solvent. The solvent system may include water. The non-aqueous solvent can include, but is not limited to polyols and glycols and associated mixtures thereof. Pharmaceutical additives such as flavorings, colorants, buffers, preservatives and mixtures thereof may be optionally added to the methylphenidate solution.
Inventor(s): Herman; Clifford J. (St. Louis, MO)
Assignee: Mallinckrodt Inc. (Hazelwood, MO)
Application Number:10/554,133
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 7,691,880

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Specgx Llc METHYLIN methylphenidate hydrochloride SOLUTION;ORAL 021419-001 Dec 19, 2002 AA RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Specgx Llc METHYLIN methylphenidate hydrochloride SOLUTION;ORAL 021419-002 Dec 19, 2002 AA RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,691,880

PCT Information
PCT FiledOctober 07, 2004PCT Application Number:PCT/US2004/033268
PCT Publication Date:April 21, 2005PCT Publication Number: WO2005/035000

International Family Members for US Patent 7,691,880

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 526988 ➤ Try a Free Trial
Australia 2004280240 ➤ Try a Free Trial
Canada 2540052 ➤ Try a Free Trial
China 1867359 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
Moodys
Cerilliant
AstraZeneca
Farmers Insurance
Chinese Patent Office
Colorcon
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.